🇺🇸 FDA
Patent

US 10239837

Piperidine derivatives as HDAC1/2 inhibitors

granted A61PA61P35/00A61P35/02

Quick answer

US patent 10239837 (Piperidine derivatives as HDAC1/2 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regenacy Pharmaceuticals, Inc.
Grant date
Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61P, A61P35/00, A61P35/02, A61P43/00, A61P7/00